These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28124511)

  • 41. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
    Yoshida EM; Kwo P; Agarwal K; Duvoux C; Durand F; Peck-Radosavljevic M; Lilly L; Willems B; Vargas H; Kumar P; Brown RS; Horsmans Y; De-Oertel S; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault N; Rizzetto M; Müllhaupt B
    Ann Hepatol; 2017; 16(3):375-381. PubMed ID: 28425407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
    Gerber L; Estep M; Stepanova M; Escheik C; Weinstein A; Younossi ZM
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):156-64.e3. PubMed ID: 26241510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.
    Wilder JM; Jeffers LJ; Ravendhran N; Shiffman ML; Poulos J; Sulkowski MS; Gitlin N; Workowski K; Zhu Y; Yang JC; Pang PS; McHutchison JG; Muir AJ; Howell C; Kowdley K; Afdhal N; Reddy KR
    Hepatology; 2016 Feb; 63(2):437-44. PubMed ID: 26547499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
    Pillai AA; Maheshwari R; Vora R; Norvell JP; Ford R; Parekh S; Cheng N; Patel A; Young N; Spivey JR; Mgbemena O; Wedd JP
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1427-1432. PubMed ID: 28382751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
    Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.
    Colombo M; Aghemo A; Liu H; Zhang J; Dvory-Sobol H; Hyland R; Yun C; Massetto B; Brainard DM; McHutchison JG; Bourlière M; Peck-Radosavljevic M; Manns M; Pol S
    Ann Intern Med; 2017 Jan; 166(2):109-117. PubMed ID: 27842383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.
    Moon J; Hyland RH; Zhang F; Brainard DM; Lanzkron S; McHutchison JG; Sulkowski M
    Clin Infect Dis; 2017 Sep; 65(5):864-866. PubMed ID: 28505305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
    Ingiliz P; Christensen S; Kimhofer T; Hueppe D; Lutz T; Schewe K; Busch H; Schmutz G; Wehmeyer MH; Boesecke C; Simon KG; Berger F; Rockstroh JK; Schulze zur Wiesch J; Baumgarten A; Mauss S
    Clin Infect Dis; 2016 Nov; 63(10):1320-1324. PubMed ID: 27535952
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
    Scott LJ
    Drugs; 2018 Feb; 78(2):245-256. PubMed ID: 29380288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
    Razafindrazoto CI; Rasolonjatovo AS; Rabenjanahary TH; Randriamifidy NH; Rakotozafindrabe ALR; Razafimahefa SH; Ramanampamonjy RM
    Int J Infect Dis; 2021 Jun; 107():166-169. PubMed ID: 33895411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
    Cooper C; Naggie S; Saag M; Yang JC; Stamm LM; Dvory-Sobol H; Han L; Pang PS; McHutchison JG; Dieterich D; Sulkowski M
    Clin Infect Dis; 2016 Aug; 63(4):528-31. PubMed ID: 27225242
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
    Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
    Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
    Naggie S; Cooper C; Saag M; Workowski K; Ruane P; Towner WJ; Marks K; Luetkemeyer A; Baden RP; Sax PE; Gane E; Santana-Bagur J; Stamm LM; Yang JC; German P; Dvory-Sobol H; Ni L; Pang PS; McHutchison JG; Stedman CA; Morales-Ramirez JO; Bräu N; Jayaweera D; Colson AE; Tebas P; Wong DK; Dieterich D; Sulkowski M;
    N Engl J Med; 2015 Aug; 373(8):705-13. PubMed ID: 26196665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
    Gane EJ; Shiffman ML; Etzkorn K; Morelli G; Stedman CAM; Davis MN; Hinestrosa F; Dvory-Sobol H; Huang KC; Osinusi A; McNally J; Brainard DM; McHutchison JG; Thompson AJ; Sulkowski MS;
    Hepatology; 2017 Oct; 66(4):1083-1089. PubMed ID: 28498551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
    Younossi ZM; Stepanova M; Omata M; Mizokami M; Walters M; Hunt S
    Medicine (Baltimore); 2016 Aug; 95(33):e4243. PubMed ID: 27537553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.